..
(). , 1000 , 200 . 2 : 1) 2) , , , . , , ; . , .
() 1000 , 200 [1]. . : , , , , , , , , , , , , , , , , , , , , , , , , , , , , .
. , , , , [2,3]. , , . 40 , , , [3,4,5]. [5].
, 40% 25% [6-9]. , 0,3 100000 [10], , . , , 20 (1974-94 .), , 4,2% (n = 943) (n = 22455) [11]. , , 13,92.4 100000 , 8,11,5; 16 , [12].
, , . , ( , , ..), . 15 [13], . 52 , - [14].
|
|
, , 1:600 1:1350 2-3% , [6].
, , 1:100 1:1000 1:10000 1:100000 [1-4,15]. , . , 205 , 57% 20 [11]. , , , , . , . , / , . , , 7,4% , .
, , , , , , () [12]. /, [16].
. , [17,18].
/ [17,19]. -, [20]. , , , , ( .) [3,17,21]. , [17,20,22]. , , , , , , , [20]. 3,2 100000 , 1,4 100000 [23].
|
|
, [24]. , , , - . , [25], 2002 . [26,27].
15 30 0,4% [28]. 6-12 1,5% . [6].
1985 2001 . Helsinn Healthcare 195 , 123 72 [25]. , 304 . , .. 0,1 100000 . , , .
, 835 . , [29]. 1,3 , 1,9 .
. 4 , [30].
, [15]. , [31,32]. , . , - [33]. [34]. - [35]. [36].
50 [11,37]. , , [38].
3 : , . (), () (, ). , , , ; ; ; ; ; . [39]. , , .
, . , , , , , [2]. . , .
|
|
, , . , 2 : 1) 2) , , , .
, , . , , , , .
, , . , . , .
, , 2 . , , , , . P450. , . , CYP2E1, , , . , , . , , . , , , . , [2].
[41]. , CYP2D6 , CYP2C19 . , N- 2, . , .
. , , , [25]. , [42].
|
|
. , , , , , , , [42].
1-8 12 . . , . , , . , , , , [2].
, [1-4,6]. , , . .
- , . , , , , , . , , . , , . .
. . . 5-10% P450 ( CYP2E1 CYP3A4) N--p- (NAPQI), [43]. NAPQI, , .
, NAPQI , . 10-15 4 . , , , P450 , .
NAPQI [44]. CYP2E1 [45], [46], [47]. [48]. , , / CYP2E1 [49].
NAPQI , CYP2E1 [50,51]. [49].
, , , .. 2-5 . 25 . , .
, , , [49]. . , [52]. 120-150 / [53].
|
|
, , [1-4]. , , , . , .. , , , , , , , . .
, , 20% [6]. 1-2% . 35 , . , , . , , , , 1 , - . . , . .
CYP2E1. CYP2E1 c1/c1 (20%; 2,52), 2 (CYP2E1 c1/c2 c2/c2; 9,0%; = 0,009) [53].
, [54]. , 1980-83 . 9,0% (10/111), 1987-88 . 17,6% (23/131), 1991-92 . 21,1% (26/123), 1998-2000 . 27,4% (32/117). .
- , [2]. . , : , , . , , - , .
, . , , . CYP2E1. , . .
[39]. , .. , , , , , , , , , , , , , /, , , ( , ) . [55,56].
- ( ), () () ( ). , , [57].
. - ( ) , , , , . , .
, , . , / .
- . , , , [58]. , , .
1% , . , , . . , , . , , -. , . , , .
. . , . . . , , , C-17 OH-. 1-2% , , , , . , -, , , .
: , , , , , .
, ( ), /, (, , .) , , [19,20]. , [20].
(, , , , , , .) , , [2-4,6,8]. .
3 1-2% , , [59,60]. , . , ( ), , , , , P450, . .
[61,62]. , , , , . [61]. . , . - ( 6 ) , -, . . , b- , . CYP2D6, . , , , , .
, , .
, , , [2]. ( ) . , 3 . . , , , ( 300 ) [4]. , , [62]. .
, . , , [61]. . . , , , , 1,5-2 . .
[2]. , [2].
, [40]. -, . [63].
[63]. , , - [63].
III 25-45% [63]. 2% , , , [64]. ( 1 ) 50% [63]. , , , .
[40,65,66]. , , , , , Jin Bu Huan Ma-Huang.
,
( , , , -, , ). , , [13]:
1. :
o 5 90 ;
o 90 .
2. :
o 50% 8 ;
o 50% 30 180
3. , .
4. ( , 2 ), .
, . , 3 . , , . , . P450, .
[67]. . . , 3 , . , . . , , , 2 /. , , .. , , , , ..
, . - , , 10% [40]. . . , N- 10 , . 16-20 , , 36-48 [49]. N- (140 /, 70 / 4 3 ) ( 300 / 20 , 50% 15 ).
, , , , [68]. , , . , , .
[58]. , , . , . , , .
, .52, , , . .52 - , .. Na+/K+- [69], . , , , .52 [70].
1. Biour M, Jaillon P. [Drug-induced hepatic diseases]. Pathol Biol (Paris) 1999;47:928-37.
2. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002;6:467-86.
3. Barbare JC, Imbert A, Benkirane A. [Hepatotoxicity of medications]. Presse Med 2001;30:673-6.
4. Teschke R. [Drug-induced liver diseases]. Z Gastroenterol 2002;40:305-26.
5. Higgins PD, Fontana RJ. Liver transplantation in acute liver failure. Panminerva Med 2003;45:85-94.
6. Dossing M, Sonne J. Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Saf 1993;9:441-9.
7. Farwell GC. Drug-induced hepatic injury. Gastroenterol Hepatol 1997;12:S242-50.
8. Denk H. [Drug-induced liver injury]. Verh Dtsch Ges Pathol 2002;86:120-5.
9. Vaquero J, Blei AT. Etiology and management of fulminant hepatic failure. Curr Gastroenterol Rep 2003;5:39-47.
10. Crombie DL. Monitoring adverse drug reactions. J R Coll Gen Pract 1975;25:337-43.
11. Pillans PI. Drug associated hepatic reactions in New Zealand: 21 years experience. NZ Med J 1996;9:315-9.
12. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-5.
13. Benichou, C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-6.
14. Aithal GP, Rawlins MD, Day Ch-P. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 1999;319:1541.
15. Teoh NC, Farrell GC. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin Liver Dis 2003;7:401-13.
16. Hartleb M, Biernat L, Kochel A. Drug-induced liver damage - a three-year study of patients from one gastroenterological department. Med Sci Monit 2002;8:CR292-6.
17. Thiim M, Friedman LS. Hepatotoxicity of antibiotics and antifungals. Clin Liver Dis 2003;7:381-99.
18. Boelsteri UA. Mechanisms of NSAID-induced hepatotoxicity. Focus on nimesulide. Drug Saf 2002;25:633-48.
19. Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects - review of the literature. Eur J Med Res 2001;6:139-49.
20. Hautekeete ML. Hepatotoxicity of antibiotics. Acta Gastroenterol Belg. 1995;58:290-6.
21. Sulkowski MS. Hepatotoxicity Associated with Antiretroviral Therapy Containing HIV-1 Protease Inhibitors. Semin Liver Dis 2003;23:183-94.
22. Amit G, Cohen P, Ackerman Z. Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J 2002;4:184-6.
23. Bradbury BD, Jick SS. Itraconazole and fluconazole and certain rare, serious adverse events. Pharmacotherapy 2002;22:697-700.
24. Manoukian AV, Carson JL. Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention. Drug Saf 1996;15:64-71.
25. Boelsteri UA. Mechanisms of NSAID-induced hepatotoxicity. Focus on nimesulide. Drug Saf 2002;25:633-48.
26. National Agency for Medicine (Finland). www.nam.fi/english/news/press_releases/nimed.html.
27. Agencia Espanola del Medicamento. www.msc.es/agemed/csmh/notas/nimesulida.asp.
28. Rainsford KD. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 1999;107(6A):27S-35S.
29. Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003;327:18-22.
30. Grieco A, Miele L, Giorgi A, et al. Acute cholestatic hepatitis associated with celecoxib. Ann Pharmacother 2002;36:1887-9.
31. Lewis JH. Drug-induced liver disease. Med Clin North Am 2000;84:1275-311.
32. Grunhage F, Fischer HP, Sauerbruch T, Reichel C. [Drug- and toxin-induced hepatotoxicity]. Z Gastroenterol 2003;41:565-78.
33. Basile G, Villari D, Gangemi S, et al. Candesartan cilexetil-induced severe hepatotoxicity. J Clin Gastroenterol 2003;36:273-5.
34. Su CW, Wu JC, Huang YH, et al. Zafirlukast-induced acute hepatitis. Zhonghua Yi Xue Za Zhi (Taipei) 2002;65:553-6.
35. Asconape JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol 2002;22:27-39.
36. Henann NE, Zambie MF. Gatifloxacin-associated acute hepatitis. Pharmacotherapy 2001;21:1579-82.
37. Conforti A, Leone R, Ghiotto E, et al. Spontaneous reporting of drug-related hepatic reactions from two Italian regions (Lombardy and Veneto). Dig Liver Dis 2000;32:716-23.
38. Buratti S, Lavine JE. Drugs and the liver: advances in metabolism, toxicity, and therapeutics. Curr Opin Pediatr 2002;14:601-7.
39. Denk H. [Drug-induced liver injury]. Verh Dtsch Ges Pathol 2002;86:120-5.
40. Farwell GC. The clinicopathological spectrum of drug-induced liver diseases. Drug-induced liver disese, ed by GC Farewell, Churchill Livingstone, London, p:101, 1994.
41. Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997;26(suppl. 2):12-21.
42. Reilly TP, Brady JN, Marchik MR, et al. A protective role for cyclooxegenase-2 in drug-induced liver injury in mice. Chem Res Toxicol 2001;14:1620-8.
43. Corcoran GB, Mitchell JR, Vaishnav YN, Horning EC. Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinoneimine. Mol Pharmacol 1980;18:536-42.
44. Brown BL, Allis JW, Simmons JE, House DE. Fasting for less than 24 h induces cytochrome P450 2E1 and 2B1/2 activities in rats. Toxicol Lett 1995;81:39-44.
45. Zhang W, Parentau H, Greenly RL, et al. Effect of protein-calorie malnutrition on cytochromes P450 and glutathione S-transferase. Eur J Drug Metab Pharmacokinet 1999;24:141-147.
46. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994;56:359-367.
47. Song BJ, Veech RL, Saenger P. Cytochrome P450IIE1 is elevated in lymphocytes from poorly controlled insulin-dependent diabetics. J Clin Endocrinol Metab 1990;71:1036-40.
48. Sauerwein RW, Mulder JA, Mulder L, et al. Inflammatory mediators in children with protein-energy malnutrition. Am J Clin Nutr 1997;65:1534-9.
49. American Academy of Pediatrics. Acetaminophen Toxicity in Children Pediatrics. 2001; 108:1020-4.
50. Ueshima Y, Tsutsumi M, Takase S, et al. Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. Alcohol Clin Exp Res 1996;20(suppl. 1):25A-28A.
51. Spielberg SP. Acetaminophen toxicity in lymphocytes heterozygous for glutathione synthetase deficiency. Can J Physiol Pharmacol 1985;63:468-71.
52. Rivera-Penera T, Gugig R, Davis J, et al. Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity. J Pediatr 1997;130:300-4.
53. Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003;37:924-30.
54. Nagayama N, Masuda K, Baba M, et al. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin]. Kekkaku 2003;78:339-46.
55. Levy C, Lindor KD. Drug-induced cholestasis. Clin Liver Dis 2003;7:311-30.
56. Grieco A, Forgione A, Giorgi A, et al. Propafenone-related cholestatic hepatitis in an elderly patient. Ital Heart J 2002;3:431-4.
57. Erlinger S. Drug-induced cholestasis. J Hepatol 1997;26(suppl. 1):1-4.
58. Chitturi S, Farrell GC. Drug-induced cholestasis. Semin Gastrointest Dis 2001;122:113-24.
59. Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 2003;7:415-33.
60. Andrejak M, Gras V, Massy ZA, Caron J. [Adverse effects of statins]. Therapie 2003;58:77-83.
61. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002;22:185-94.
62. Stravitz RT, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2003;7:435-51.
63. Michielsen PP, Fierens H, Van Maercke YM. Drug-induced gallbladder disease. Incidence, aetiology and management. Drug Saf 1992;7:32-45.
64. Genesse C, Finelli L, Parkin W, Spitalny KC. Ceftriaxone-assosiated biliary complications of treatment of suspected disseminated Lyme disease. JAMA 1993;269:979-83.
65. Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis 2000;4:73-96.
66. Sleeper RB, Kennedy SM. Adverse reaction to a dietary supplement in an elderly patient. Ann Pharmacother 2003;37:83-6.
67. Ryan M, Desmond P. Liver toxicity. Could this be a drug reaction? Aust Fam Physician 2001;30:427-31.
68. Altuntas Y, Ozturk B, Erdem L, et al. Phenytoin-induced toxic cholestatic hepatitis in a patient with skin lesions: case report. South Med J 2003;96:201-3.
69. Kala Suhas Kulkarni et al. Protective effect of Liv.52 on Na+-K+-ATPase activity in Paracetamol-induced Hepatotoxicity. Medicine Update (2002): (10), 5, 53-56].
70. Brij Kishore, Hazra, D.U., Sachan, A.S., Agrawal, B.M., Bharadwaj, A.K., Ashok Kumar and Mehrotra, M.M.N.,The Effect of Liv.52 on Liver Functions of Tubercular Patients Receiving Second Line Anti-Tubercular Drugs. Probe (1978): (XVII), 2, 125-131